Ortek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor.
Learn MoreTraverse Biosciences has announced a collaboration with SUNY Updated Medical University on a Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense.
Learn MoreThe next HHS SBIR/STTR application deadline is less than two months away – start thinking about your application today. Registration can take weeks so start now and be sure to talk to a program manager for advice.
Learn MoreIntensity Therapeutics has announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices.
Learn MoreThe Center for Biotechnology team recently attended the BIO International Convention in San Francisco and supported the participation of emerging companies and faculty entrepreneurs in the event.
Learn MoreRgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.
Learn More